SCHEMBL23910751

SCHEMBL23910751

O=C(Cl)C1Cc2cc(Cl)cc(Br)c2O1

nearest known ligand 0.38

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 8/20 0.38
USP7 Q93009 6/20 0.35
MCL1 Q07820 1/20 0.33
EZH2 Q15910 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23911362 1.00 SIRT2 (0.38) SIRT2USP7MCL1EZH2
SCHEMBL23910855 0.88 SMN1; SMN2 (0.40) SIRT2USP7MCL1
SCHEMBL23911295 0.88 SIRT2 (0.38) SIRT2USP7MCL1
SCHEMBL23910858 0.88 SMN1; SMN2 (0.40) SIRT2USP7MCL1
SCHEMBL23911175 0.85 NFKB1 (0.39) SIRT2MCL1
SCHEMBL23911178 0.85 NFKB1 (0.39) SIRT2MCL1
SCHEMBL23911385 0.78 USP7 (0.45) SIRT2USP7
SCHEMBL23911381 0.78 USP7 (0.45) SIRT2USP7
SCHEMBL23910670 0.76 NFKB1 (0.39) SIRT2MCL1
SCHEMBL23910714 0.76 NFKB1 (0.39) SIRT2MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210317134-A1 UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF RAPT THERAPEUTICS INC (US) 2021-10-14 US disclosed
US-20210317134-A1 UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF RAPT THERAPEUTICS INC (US) 2021-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317134-A1 UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF USP7, SENP7, USP8 SIRT2 2369/4885USP7 1/4885MCL1 572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.